Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
By J. Cortés, J. O’Shaughnessy, D. Loesch, J. Blum, L. Vahdat, K. Petráková, P. Chollet, A. Manikas, V. Diéras, T. Delozier and 10 more. The Lancet, 2011
981 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/79799a6a0b0a3282919f2007a2ba9fcecc4623cc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, result): “Eribulin has provided an OS benefit in heavily pretreated patients (up to 5 lines of treatment) [115] and similar PFS and OS results to capecitabine after prior treatment with an anthracycline and taxane [116].”
- NATURAL PRODUCTS: A CONTINUING SOURCE OF NOVEL DRUG LEADS (2013, background): “Details of the pivotal clinical trial leading to this approval have recently been published and can be consulted by interested readers [56].”
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “99) 2 [98]”
- An overview of triple-negative breast cancer (2016, background): “The majority (74 %) of patients enrolled in the trial were HER2 negative and 19 % had TNBC [134].”
- Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation (2014, background): “The tumor response rate to eribulin was 13%, and patients had received a median of four prior chemotherapy regimens.(17) Limited data are available on the activity of olaparib in platinumresistant or -refractory ovarian cancer.”